Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 3284 entries
View as:

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03159442 Org: User:
Start: 06/19/17 End: 10/13/17 Due: 10/13/18

An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00721448 Org: User:
Start: 06/30/08 End: 08/31/08 Due: 08/31/09

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT00704366 Org: User:
Start: 06/30/08 End: 05/31/11 Due: 05/31/12

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01112397 Org: User:
Start: 04/30/10 End: 09/30/12 Due: 09/30/13

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

Phase: N/A Priority: Normal
NCT ID: NCT01594619 Org: User:
Start: 05/31/12 End: 08/31/12 Due: 08/31/13

The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.

Phase: N/A Priority: Normal
NCT ID: NCT02336607 Org: User:
Start: 12/31/05 End: 08/31/06 Due: 08/31/07

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02777658 Org: User:
Start: 05/26/16 End: 05/31/20 Due: 05/31/21

Europe-Japan Diagnostic Study for EGFR Testing

Phase: N/A Priority: Normal
NCT ID: NCT01785888 Org: User:
Start: 04/30/13 End: 04/30/14 Due: 04/30/15

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04877691 Org: User:
Start: 06/08/21 End: 11/18/26 Due: 11/18/27

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00748982 Org: User:
Start: 08/31/08 End: 07/31/09 Due: 07/31/10

Add-on to Thiazolidinedione (TZD) Failures

Phase: N/A Priority: Normal
NCT ID: NCT00683878 Org: User:
Start: 07/31/08 End: 06/30/10 Due: 06/30/11

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Phase: N/A Priority: Normal
NCT ID: NCT00308139 Org: User:
Start: 04/30/06 End: 08/31/14 Due: 08/31/15

Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain

Phase: N/A Priority: Normal
NCT ID: NCT07013760 Org: User:
Start: 06/30/25 End: 12/31/25 Due: 12/31/26

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00672399 Org: User:
Start: 04/30/08 End: 07/31/08 Due: 07/31/09

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00257205 Org: User:
Start: 03/31/06 End: 08/31/10 Due: 08/31/11

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01081496 Org: User:
Start: 03/31/10 End: 02/28/11 Due: 02/28/12

Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01007734 Org: User:
Start: 10/31/09 End: 07/31/10 Due: 07/31/11

Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN

Phase: N/A Priority: Normal
NCT ID: NCT00831909 Org: User:
Start: 01/31/09 End: 07/31/10 Due: 07/31/11

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01929603 Org: User:
Start: 12/31/13 End: 11/30/16 Due: 11/30/17

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05166421 Org: User:
Start: 11/30/21 End: 07/19/23 Due: 07/19/24

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Phase: N/A Priority: Normal
NCT ID: NCT00759395 Org: User:
Start: 01/31/09 End: 10/31/11 Due: 10/31/12

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase: N/A Priority: Normal
NCT ID: NCT06346392 Org: User:
Start: 03/04/24 End: 10/09/26 Due: 10/09/27

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Phase: N/A Priority: Normal
NCT ID: NCT02010970 Org: User:
Start: 12/31/13 End: 02/28/14 Due: 02/28/15

Relative Bioavailability of Phase II and Phase III Formulations of AZD0530

Phase: N/A Priority: Normal
NCT ID: NCT00771979 Org: User:
Start: 11/30/08 End: 03/31/09 Due: 03/31/10

A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00690287 Org: User:
Start: 02/29/08 End: 06/30/08 Due: 06/30/09